These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
268 related items for PubMed ID: 18196747
21. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs. Rassnick KM, Bailey DB, Malone EK, Intile JL, Kiselow MA, Flory AB, Barlow LL, Balkman CE, Barnard SM, Waite AH. Vet Comp Oncol; 2010 Dec; 8(4):243-53. PubMed ID: 21062406 [Abstract] [Full Text] [Related]
22. Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol. Veluvolu S, Pellin M, Vos N. J Am Vet Med Assoc; 2021 Sep 01; 259(5):494-502. PubMed ID: 34388019 [Abstract] [Full Text] [Related]
23. Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma. Marquardt TM, Lindley SES, Smith AN, Cannon CM, Rodriguez CO, Thamm DH, Childress MO, Northrup NC. J Am Vet Med Assoc; 2019 Jan 15; 254(2):236-242. PubMed ID: 30605381 [Abstract] [Full Text] [Related]
28. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. Saba CF, Thamm DH, Vail DM. J Vet Intern Med; 2007 Jan 15; 21(1):127-32. PubMed ID: 17338160 [Abstract] [Full Text] [Related]
31. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). Rassnick KM, Mauldin GE, Al-Sarraf R, Mauldin GN, Moore AS, Mooney SC. J Vet Intern Med; 2002 Jan 15; 16(5):576-80. PubMed ID: 12322709 [Abstract] [Full Text] [Related]
34. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin. Valerius KD, Ogilvie GK, Fettman MJ, Walton JA, Richardson K, Powers BE, McNiel EA, Rogers QR. J Am Vet Med Assoc; 1999 Feb 01; 214(3):353-6. PubMed ID: 10023395 [Abstract] [Full Text] [Related]
35. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. J Clin Oncol; 2005 Mar 20; 23(9):1984-92. PubMed ID: 15668467 [Abstract] [Full Text] [Related]
38. A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma. Moore AS, Cotter SM, Frimberger AE, Wood CA, Rand WM, L'Heureux DA. J Vet Intern Med; 1996 Mar 20; 10(6):372-5. PubMed ID: 8947869 [Abstract] [Full Text] [Related]
40. Response-based modification of CHOP chemotherapy for canine B-cell lymphoma. Benjamin SE, Sorenmo KU, Krick EL, Salah P, Walsh KA, Weinstein NM, Keuler NS, Avery AC, Atherton MJ, Lenz JA. Vet Comp Oncol; 2021 Sep 20; 19(3):541-550. PubMed ID: 33729654 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]